$1.91
Alx Oncology Holdings is a biotechnology business based in the US. Alx Oncology Holdings shares (ALXO) are listed on the NASDAQ and all prices are listed in US Dollars. Alx Oncology Holdings employs 81 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Alx Oncology Holdings stock
How to buy Alx Oncology Holdings stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ALXO. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Alx Oncology Holdings stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Alx Oncology Holdings stock price (NASDAQ: ALXO)
Use our graph to track the performance of ALXO stocks over time.Alx Oncology Holdings shares at a glance
Latest market close | $1.99 |
---|---|
52-week range | $2.25 - $17.83 |
50-day moving average | $4.69 |
200-day moving average | $10.92 |
Wall St. target price | $9.33 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-3.65 |
Is it a good time to buy Alx Oncology Holdings stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Alx Oncology Holdings price performance over time
Historical closes compared with the close of $1.99 from 2024-09-05
1 week (2024-08-30) | -14.22% |
---|---|
1 month (2024-08-07) | -22.57% |
3 months (2024-06-07) | -77.91% |
6 months (2024-03-07) | -87.75% |
1 year (2023-09-07) | -59.96% |
---|---|
2 years (2022-09-07) | -83.57% |
3 years (2021-09-07) | 74.82 |
5 years (2019-09-03) | N/A |
Alx Oncology Holdings financials
Gross profit TTM | $107,000 |
---|---|
Return on assets TTM | -49.01% |
Return on equity TTM | -92.17% |
Profit margin | 0% |
Book value | $3.04 |
Market Capitalization | $122.2 million |
TTM: trailing 12 months
Alx Oncology Holdings share dividends
We're not expecting Alx Oncology Holdings to pay a dividend over the next 12 months.
Alx Oncology Holdings share price volatility
Over the last 12 months, Alx Oncology Holdings 's shares have ranged in value from as little as $2.245 up to $17.825. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alx Oncology Holdings 's is 1.016. This would suggest that Alx Oncology Holdings 's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Alx Oncology Holdings overview
ALX Oncology Holdings Inc. , a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc.
Frequently asked questions
nullWhat percentage of Alx Oncology Holdings is owned by insiders or institutions?
Currently 1.915% of Alx Oncology Holdings shares are held by insiders and 109.106% by institutions. How many people work for Alx Oncology Holdings ?
Latest data suggests 81 work at Alx Oncology Holdings . When does the fiscal year end for Alx Oncology Holdings ?
Alx Oncology Holdings 's fiscal year ends in December. Where is Alx Oncology Holdings based?
Alx Oncology Holdings 's address is: 323 Allerton Avenue, South San Francisco, CA, United States, 94080 What is Alx Oncology Holdings 's ISIN number?
Alx Oncology Holdings 's international securities identification number is: US00166B1052
More guides on Finder
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
7 best day trading platforms of 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for beginners: 11 best trading platforms to get started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 best discount brokers of 2024 for low-cost trading and investing
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
10 best stock apps of 2024 to elevate your mobile trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 best brokerage accounts for buying stocks, options and more in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question